Hanson & Doremus Investment Management maintained its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,191 shares of the medical research company’s stock at the close of the 2nd quarter. Hanson & Doremus Investment Management’s holdings in Amgen were worth $205,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Amgen by 1.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after buying an additional 45,403 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares during the period. Swiss National Bank increased its stake in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Amgen by 0.7% in the first quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after buying an additional 10,109 shares during the period. 78.10% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/25/amgen-inc-amgn-stake-maintained-by-hanson-doremus-investment-management.html.

Amgen Inc. (AMGN) opened at 185.76 on Monday. The stock has a 50 day moving average price of $175.99 and a 200-day moving average price of $169.31. The company has a market cap of $135.54 billion, a price-to-earnings ratio of 16.92 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.84 EPS. On average, analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were paid a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.48%. Amgen’s payout ratio is currently 41.93%.

Several brokerages have recently weighed in on AMGN. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 target price on shares of Amgen in a research note on Thursday, September 7th. Leerink Swann reaffirmed a “market perform” rating and set a $161.00 target price on shares of Amgen in a research note on Thursday, June 22nd. Credit Suisse Group set a $177.00 target price on Amgen and gave the stock a “hold” rating in a research note on Friday, July 14th. Finally, UBS AG set a $180.00 target price on Amgen and gave the stock a “hold” rating in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $186.14.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.